3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Sarcoma
1341
Glioblastoma
493
Gliosarcoma
470
Osteosarcoma
364
Brain Neoplasms
321
Central Nervous System Neoplasms
276
Astrocytoma
262
Dendritic Cell Sarcoma, Interdigitating
258
Gastrointestinal Stromal Tumors
252
Neoplasms
231
Glioma
230
Lymphoma
227
Rhabdomyosarcoma
209
Neuroblastoma
209
Breast Neoplasms
205
Sarcoma, Ewing
203
Recurrence
202
Burkitt Lymphoma
198
Lymphoma, Non-Hodgkin
196
Precursor Cell Lymphoblastic Leukemia-Lymphoma
195
Oligodendroglioma
192
Melanoma
183
Ovarian Neoplasms
177
Lymphoma, Large B-Cell, Diffuse
173
Neoplasm Metastasis
172
Bone Neoplasms
169
Lymphoma, Follicular
158
Liposarcoma
144
Leukemia, Lymphocytic, Chronic, B-Cell
144
Lymphoma, Mantle-Cell
143
Interventions
mifamurtide
1
Temozolomide
1
Irinotecan
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Bone Tissue
×
Sarcoma
×
Clear all
NCT03643133
2026-05-19
SARCOME13
UNICANCER
Phase 2
Active not recruiting
60 enrolled
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts